Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Carcinoma, Hepatocellular 9Esophageal Neoplasms 7Stomach Neoplasms 4Small Cell Lung Carcinoma 4Rectal Neoplasms 4Nasopharyngeal Carcinoma 4Colorectal Neoplasms 4Neoplasms 3Esophageal Squamous Cell Carcinoma 3Colonic Neoplasms 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Hodgkin Disease 2Glioblastoma 2mCRPC 1Uterine Cervical Neoplasms 1Unresectable Stage III Non-small Cell Lung Cancer 1Tongue Squamous Cell Carcinoma 1SCLC, Extensive Stage 1Rare Tumour 1Non-Muscle Invasive Bladder Neoplasms 1Non Squamous Non-small Cell Lung Cancer 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1NSCLC 1MSI-H Colorectal Cancer 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1

Interventions

Drug Therapy 3Carboplatin 3Surgical Procedures, Operative 2Pemetrexed 2Paclitaxel 2Cisplatin 2toripalimab 1tislelizumab 1surufatinib 1osimertinib 1lorlatinib 1anlotinib 1aflutinib 1Radiotherapy 1Radiosurgery 1Platinum Compounds 1Neoadjuvant Therapy 1Diphenhydramine 1Cryotherapy 1Chemotherapy, Adjuvant 1Chemoradiotherapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × NSCLC × tislelizumab × Clear all
NCT06414915 2024-05-16

Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation

National Cancer Center, China

Phase 2 Not yet recruiting
29 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡